Advertisement

Topics

"Building Pipeline∨derfield=date∨derval=DESC" News Stories

18:07 EDT 15th July 2019 | BioPortfolio

Here are the most relevant search results for "Building Pipeline∨derfield=date∨derval=DESC" found in our extensive news archives from over 250 global news sources.

More Information about Building Pipeline∨derfield=date∨derval=DESC on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Building Pipeline∨derfield=date∨derval=DESC for you to read. Along with our medical data and news we also list Building Pipeline∨derfield=date∨derval=DESC Clinical Trials, which are updated daily. BioPortfolio also has a large database of Building Pipeline∨derfield=date∨derval=DESC Companies for you to search.

Showing "Building Pipeline derfield date derval DESC" News Articles 1–25 of 10,000+

Monday 15th July 2019

$5.1B R&D collaboration lets @GileadSciences expand stake in @GalapagosNV, role in filgotinib, access to partner's pipeline: http://ow.ly/N8wL50v10hk 

$5.1B R&D collaboration lets @GileadSciences expand stake in @GalapagosNV, role in filgotinib, access to partner's pipeline: http://ow.ly/N8wL50v10hk 


Global Medical REIT Inc. Schedules Release of Its 2019 Second Quarter Financial Results and Conference Call

Live Conference Call Thursday August 8, 2019 at 9:00 AM ET Global Medical REIT Inc. (NYSE: GMRE) (the “Company” or “GMRE”), a net-lease medical office real estate investment trust (REIT) that acquires purpose-built healthcare facilities and leases those facilities to strong healthcare systems and groups with leading market share, announced today that it intends to release its second quar...

vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral presentation at the 2019 Alzheimer's Association International Conference (AAI


CynergisTek, Inc. Announces Retirement of Founder and Thought Leader Mac McMillan and Appoints His Successor Caleb Barlow as President & Chief Executive Officer to Lead the Company’s Next Stage of Growth

CynergisTek, Inc. (NYSE AMERICAN: CTEK), today announced the appointment of Caleb Barlow to the positions of President and Chief Executive Officer, to succeed retiring founder and current President and CEO Mac McMillan effective August 1, 2019. McMillan will support Barlow in the execution of CynergisTek’s strategy through the remainder of 2019 and will remain a member of the Board of Directors...

Medical Properties Trust Announces Public Offering of 45,000,000 Shares of Common Stock

Medical Properties Trust, Inc. (the “Company”) (NYSE: MPW) announced today that it has commenced an underwritten public offering to sell 45,000,000 shares of its common stock. The Company intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 6,750,000 shares of its common stock. The Company intends to use the net proceeds from the offering to part...

Medical Properties Trust Announces $1.75 Billion Investment in 24 Hospital Facilities

Year-to-Date Acquisitions of $3.0 Billion Surpasses 2019 Full Year Acquisition Goal and Establishes Record Acquisitions Year Weighted Average GAAP Rate of 8.2% for 2019 YTD Acquisitions Transactions Immediately Accretive; Increases Run Rate Guidance for Net Income to $1.08 to $1.12 and NFFO to $1.54 to $1.58 Per Share Medical Properties Trust, Inc. (“MPT” or the “Company”) (NYSE: MP...

Hodgkin Lymphoma BCell Hodgkin Lymphoma Pipeline Review, H1 2019 [Report Updated: 29032019] Prices from USD $2000

Hodgkin Lymphoma BCell Hodgkin Lymphoma Pipeline Review, H1 2019SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma BCell Hodgkin Lymphoma Pipeline Review, H1 2019, provides an overview of the Hodgkin Lymphoma BCell Hodgkin Lymphoma Oncology pipeline landscape.Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes....

Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019

Record Annual Revenue of $27 Million HACKENSACK, NJ / ACCESSWIRE / July 15, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the fourth fiscal quarter and 12 months ended April 30, 2019.

. @GileadSciences Expands @GalapagosNV Stake, Filgotinib Role, Pipeline Access in $5.1B R&D Collaboration: http://ow.ly/N8wL50v10hk pic.twitter.com/NPmczrlKNC

. @GileadSciences Expands @GalapagosNV Stake, Filgotinib Role, Pipeline Access in $5.1B R&D Collaboration: http://ow.ly/N8wL50v10hk  pic.twitter.com/NPmczrlKNC

I wrote about the design process behind building a mental health app that people might actually want to use, from animation to narration. With video from @HoganAlex https://www.statnews.com/2019/07/15/mental-health-app-podcast-pixar/ …

I wrote about the design process behind building a mental health app that people might actually want to use, from animation to narration. With video from @HoganAlex https://www.statnews.com/2019/07/15/mental-health-app-podcast-pixar/ …

His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date.  https://buff.ly/2NXAXjv 

His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date.  https://buff.ly/2NXAXjv 

AVROBIO Announces Positive Data from Clinical Trials of AVR-RD-01 Investigational Gene Therapy in Fabry Disease

CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”) today announced the first kidney biopsy result and additional positive data from two ongoing clinical trials of its AVR‑RD‑01 investigational gene therapy in Fabry disease. To date, eight patients have been dosed in the trials – three patients in the Phase 2 FAB-2011 trial and five patients in the...

Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9

Epigenomics AG / Key word(s): Patent/Legal Matter Epigenomics AG: Chinese Patent Reexamination Department partially invalidates Epigenomics' patent claims for Septin9 15-Jul-2019 / 15:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of...

Gilead Expands Galapagos Stake, Filgotinib Role, Pipeline Access in $5.1B R&D Collaboration

Gilead Sciences will shell out $5.1 billion to nearly double its minority stake in Galapagos from approximately 12.3% to at least 22%--and possibly about 30%--through a 10-year global R&D collaboration in which the co-developers of filgotinib will also co-develop the rest of the Belgian biotech’s pipeline. The post Gilead Expands Galapagos Stake, Filgotinib Role, Pipeline Access in $5.1B R&...

Paige Announces World’s First Clinical-Grade Artificial Intelligence in Pathology

Article Published in Nature Medicine Provides Further Scientific Evidence for Deployment of Computational Decision Support Systems to Improve Patient Care Paige, the leader in computational pathology focused on building artificial intelligence (AI) to transform the clinical diagnosis and treatment of cancer, today announced the publication of an article in Nature Medicine, a leading monthly jour...

Biden puts forth an elaborate — and aggressive — plan to lower drug prices 

His new platform includes some of the most aggressive approaches to lowering drug prices any Democratic presidential candidate has proposed to date. 

Gilead inks $5B deal with Galapagos to bolster pipeline of anti-inflammatories

Gilead Sciences has struck a major expansion deal with a European biotech firm to target the high-growth anti-inflammatories market.

A Biopharma Company Transforms Patient Care and Drug Development Using Patient Journey Analytics | a Success Story by Quantzig

A global data analytics and advisory firm, Quantzig, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of their latest patient journey analytics engagement for a leading biopharma client. During the course of this engagement, the analytics experts at Quantzig adopted a comprehensive approach to assessing the qualitative and quantitative...

Vericred Launches Disruption Analysis API for Health and Dental Insurance Networks

Empowering users to quickly and dynamically analyze what percentage of employees would be affected by switching networks Vericred, a data services platform powering the digital distribution of health insurance and employee benefits, announced today the immediate availability of its Disruption Analysis API. Vericred’s new API enables InsurTech companies to build decision support tools that help...

Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform.

Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers AMAL’s first-in-class proprietary KISIMA® platform leverages peptide/protein-based vaccination technology AMAL will remain at the campus of the University of Geneva in Switzerland and operate as a subsidiary within Boehringer Ingel...

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California

FDA Investigational New Drug (IND) package Worldwide, exclusive licence with long patent life Phase 1 clinical trial anticipated to commence in 2020 Ex-Viralytics members part of project team for development of the oncolytic virus SYDNEY Australia – 15 July 2019 – Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced it would acquire Vaxinia P...

HNC Celebrated its 10th Anniversary this June in Shanghai

SHANGHAI, July 15, 2019 /PRNewswire/ -- Organized by CCCMHPIE and Sinoexpo Informa Markets, HNC moved to National Exhibition and Convention Center (Shanghai) this June together with all co-located food industry shows, covering the industry chains from health food, senior care products and services, food ingredients to food processing and packaging. The wholes food series shows took 5 halls in NECC...

PhoreMost appoints Dr Lorenz Mayr as Non-Executive Director - Board appointment will help guide target identification and drug discovery

Cambridge, UK, 15 July 2019: PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has appointed Dr Lorenz Mayr to its Board as Non-Executive Director. Dr Mayr’s experience in drug discovery and development, and specifically his expertise in functional genetic screening in target identification, will...

Imugene Enhances Portfolio with Compelling Oncolytic Virus from City of Hope, a Cancer Centre in Los Angeles, California

 FDA Investigational New Drug (IND) package Worldwide, exclusive licence with long patent life Phase 1 clinical trial anticipated to commence in 2020 Ex-Viralytics members part of project team for development of the oncolytic virus Australian immuno-oncology company Imugene Ltd (ASX:IMU), today announced that it would acquire Vaxinia Pty Ltd and separately acquire a worldwide exclusive ...

Boston Children’s Hospital Forms Strategic Partnership with Premier Inc.

Boston Children’s Hospital, one of the largest pediatric medical centers in the U.S., has partnered with Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, to foster optimal management of its supply chain portfolio. Ranked the #1 children's hospital in the nation by U.S. News & World Report, Boston Children’s is the primary pediatric teaching affiliate of Harvard Med...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks